TrakCel—a software developer for cell and gene therapy supply chain tracking and orchestration systems—and WindMIL Therapeutics—a clinical-stage oncology cell therapy company—have formed a partnership to build a custom-configured cellular supply chain tracking and orchestration platform.
The platform will support the clinical development of proprietary autologous cell therapies from WindMIL and will also be used to manage the company’s entire supply chain. This clinical expansion by WindMIL follows its successful completion of a Series B financing round, in which it raised US$32.5 million in June 2018.
“We are excited to soon treat more patients with Marrow Infiltrating Lymphocytes(MILs) through this expansion of our clinical trial program. MILs harness the power of the body’s own immune system, specifically cells residing in the bone marrow. We are the only company focused on manufacturing and developing this natural source of tumor-targeting, central-memory T cells,” said Brian Halak, president and CEO, WindMIL Therapeutics in a Jan. 29, 2019, press release. “However, developing novel cellular therapies is also about logistics. It is important for us to ensure the supply chain works for each of the individuals involved in the patient’s care and for the oncology patients themselves.”
“The entire cell therapy sector now realizes the importance of managing and tracking the supply chain from an early stage. As a result, TrakCel is now working with a range of companies at the initiation of the clinical stage as well as at the late stage of clinical development,” said Ravi Nalliah, CEO of TrakCel.
